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ABSTRACT 
Labetalol is an adrenergic receptor blocking agent used in the treatment of hypertension and characterized by high solubility and high 
permeability which corresponds to BCS class I drug. Plasma half life ranges from 6 & bioavailability is 25%. Ethyl cellulose was used as a rate 
controlling polymer. Effects of addition of ethyl cellulose on in vitro dissolution were studied. Nanoparticles were formulated using different 
polymer ratios. In vitro drug release was carried out by using USP Type II at 50 rpm in 900 ml of acidic dissolution medium (pH 1.2) for 2 
hours, followed by 900 ml alkaline dissolution medium (pH7.4) for 12 hours. Mean dissolution time is used to characterize drug release rate 
from a dosage form. Several kinetic models were applied to the dissolution profiles to determine the drug release kinetics. Excipients are 
selected by FTIR studies. Finally the nanoparticles were evaluated for various characteristics like encapsulation efficiency, percentage yield, 
partial size and the In vitro release for 12 hrs.  The nanoparticles were found to be discrete, spherical, and free-flowing.  The nanoparticles 
were uniform in size, and the microencapsulation efficiency was in the range of 52.5-81.7%. The surface morphology of prepared Labetalol 
nanoparticles was observed under scanning electron Microscopy. Nanoparticles had good spherical geometry. The stability study was 
performed at 40ºC ± 2ºC and 75 ± 5% RH for 6 months. 
Keywords: Nanoparticles; Labetalol, Hypertension, Ethyl Cellulose, Dissolution, entrapment efficiency.  
 
Article Info: Received 21 Oct 2018;     Review Completed 03 Dec 2018;     Accepted 05 Dec 2018;     Available online 15 Dec 2018 
Cite this article as:  
Betala S, Varma MM, Abbulu K, Formulation and evaluation of polymeric nanoparticles of an antihypetensive drug 
labetalol, Journal of Drug Delivery and Therapeutics. 2018; 8(6-s):187-191                                                                              
DOI: http://dx.doi.org/10.22270/jddt.v8i6-s.2109                     
*Address for Correspondence:  
Surendranath Betala, Sri Vasavi Institute of Pharmaceutical Sciences, Tadepalligudem, Andrapradesh. India 
 
 
INTRODUCTION 
Nanotechnology has been introduced into several aspects 
of the food science, including apsulations and delivery 
systems, which has versatile advantages such as 
incorporation of the bioactive compounds into the food 
matrices with high physicochemical stability and minimal 
impact on the properties of the product, as well as 
protection of the encapsulated bioactive compounds from 
the interaction with other food components, and maximize 
the uptake of the encapsulated compounds upon intake 
and their transport to the sites of action. Nanoparticles are 
one of the different types of nano-sized carriers generally 
have size below than 1000 nm that being developed for 
drug delivery applications. Nanoparticles classified as non-
degradable and biodegradable. In recent years, there has 
been considerable attention to developing biodegradable 
nanoparticles due to their higher encapsulation efficiency, 
controlled release and less toxic properties. Numerous 
processes have been extensively described in past years 
for the preparation of nanoparticles, including 
emulsion/solvent evaporation, nanoprecipitation, 
emulsion and miniemulsion polymerization, salting out, 
using supercritical fluid technology, electrohydrodynamic 
atomization, and the generation of nanoparticles using the 
nano-emulsion template. The nanoprecipitation technique 
(or solvent displacement method) is a modified solvent 
evaporation method for nanoparticle production. In this 
method the water-miscible solvents like acetone or 
methanol along with the water immiscible organic solvent 
like chloroform or dichloromethane were used as an oil 
phase. Rapid dispersion of the polymers in the presence of 
water can cause precipitation of polymers. This technique 
has many advantages like rapid and easy to perform where 
the entire procedure could carry out in only one step. 
Different methodologies have been reported in the 
literature to increase the gastric retention of drugs, like 
intra-gastric floating systems, hydro dynamically balanced 
systems, extendable or expandable, micro porous 
compartment system, microballons, bio-adhesive systems, 
Betala et al                                                                                                    Journal of Drug Delivery & Therapeutics. 2018; 8(6-s):187-191 
ISSN: 2250-1177                                                                                  [188]                                                                                 CODEN (USA): JDDTAO 
high-density systems, and super porous biodegradable 
hydro gel systems. After oral administration, such a dosage 
form would be retained in the stomach for several hours 
and would release the drug there in a controlled and 
prolonged manner, so that the drug could be supplied 
continuously to its absorption sites in the upper 
gastrointestinal tract. Prolonged gastric retention 
improves bioavailability, reduces drug waste, and 
improves solubility of drugs that are less soluble in a high 
pH environment. It is also suitable for local drug delivery 
to the stomach and proximal small intestine. Gastro 
retention helps to provide better availability of new 
products with suitable therapeutic activity and substantial 
benefits for patients. The aim of the present study was to 
formulate gastro retentive nanoparticles of Labetalol to 
deliver the drug at a controlled rate to its absorption site 
so that its oral bioavailability can be enhanced. 
Mucoadhesive polymers, such as bovine serum albumin, 
chitosan, and gelatin, were selected to prepare 
gastroretentive nanoparticles as they intensify the contact 
between dosage form and the site of absorption, thereby 
reducing the luminal diffusion pathway of the drug 
(bioadhesion) and lead to significant improvements in oral 
drug delivery. These mucoadhesive polymeric 
nanoparticles in the stomach will offer various advantages 
such as (i) Longer residence time of the dosage form on 
mucosal tissues in the stomach. This will improve 
absorption of the drug and increase the drug 
bioavailability. (ii) Higher drug concentration at the site of 
adhesion absorption, which will create a driving force for 
the paracellular passive uptake. (iii) Immediate absorption 
from the bioadhesive drug delivery system without 
previous dilution and possible degradation in the luminal 
fluids. 
MATERIALS AND METHODS 
Materials 
Labetalol sample obtained from Yarrow chem. Products 
Mumbai. Polymers Ethyl cellulose from Ozone 
International Mumbai. Gelatin and Chitosan from S.D.Fine 
chemicals, Munbai and HPMC K 100M  from Loba chem.Pvt 
Ltd, Mumbai. 
Equipments 
UV-Visible spectrophotometer - Lab India Model-UV3092, 
Mumbai, Mechanical stirrer - Kshitij Innovations, Ambala 
Cantt, Sonicator - Loba Life, Mumbai, Dissolution test 
apparatus - Lab India- DS 8000, Mumbai, Analytical 
balance - Shimadzu, Japan, Hot air oven - Fortune, Mumbai, 
Stability Chamber - Remi Elektro Technik Limited, Vasai.
  
Drug Profile 
Labetalol 
Chemical Name: 2-hydroxy-5-[1-hydroxy-2-[(4-phenyl-2-
butanyl) amino]ethyl]benzamide 
Systematic (IUPAC) Formula: C19H24N2O3 
Mol. mass: 328.41 g/mol 
 
Figure 1: Structure of Labetalol structure 
Solubility: sparingly soluble in water and in ethanol 
(95%), insoluble in chloroform and ether. 
Description:              
Labetalol is a white crystalline powder. It is an adrenergic 
receptor blocker drug characterized by high solubility and 
high permeability which corresponda to BCS class 1 drug. 
It works by blocking both alpha and beta receptors in the 
body which lowers blood pressure. 
Protein binding: Plasma protein binding is 50%   
Metabolism: Primarily hepatic, undergoes significant first 
pass metabolism 
Half-life: 6 hours 
Preparation of Nanoparticles 
Nanoparticles were prepared according to the 
nanoprecipitation method with slight modification. Briefly, 
200 mg of polymer (HPMC, Ethyl cellulose, chitosan, and 
gelatin) was dissolved in 25 ml of acetone separately. The 
Labetalol 100 mg was dissolved in 2 ml of 
dimethylsulfoxide. Both solutions were mixed and then 50 
ml of water was added and stirred for a half hour. Acetone 
was eliminated by evaporation under reduced pressure 
using rotary flash evaporator and the final volume of the 
suspension was adjusted to 10 ml. Then this suspension 
was centrifuged at 15000 rpm at 4oC for half an hour. The 
supernatant was discarded and precipitate was washed 3 
times with distilled water. The nanoparticles thus obtained 
were dried overnight in oven at 60ºC and stored in a 
desiccator. The prepared formulations were characterized 
for loading efficiency, entrapment efficiency, particle size, 
particle size distribution, polydispersity index, zeta 
potential and drug excipient compatibility studies. 
Drug-Excipient Compatibility Studies 
The drug excipient compatibility studies were performed 
by using FT-IR spectrophotometer (Perkin Elmer). The FT-
IR spectra of drug, polymers, and formulations were 
analyzed separately and then correlated for 
incompatibility. 
Characterization of Labetalol Loaded 
Nanoparticles 
Loading Efficiency 
Drug content in the preparation was determined by 
extracting the drug from the nanoparticles with 0.1 M 
hydrochloric acid. In this method, the nanoparticles (50 
mg) were stirred in 50 ml of 0.1 M hydrochloric acid until 
dissolved; it was filtered through a Millipore filter and the 
drug content was determined, after suitable dilution, at 
254 nm by UV spectrophotometry. The loading efficiency 
(L) of the nanoparticles was calculated according to 
Equation 1 
L (%) = (Qn /Wn) × 100
 
…..(1) 
Where Wn is the weight of the nanoparticles and Qn is the 
amount of drug present in the nanoparticles. 
Entrapment Efficiency 
For determination of drug entrapment, the amount of drug 
present in the clear supernatant after centrifugation was 
determined (w) by UV spectrophotometer at 254 nm. A 
standard calibration curve of drug was plotted for this 
purpose. The amount of drug in supernatant was then 
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subtracted from the total amount of drug added during the 
preparation (W). Effectively, (W-w) will give the amount of 
drug entrapped in the particles. 
Then percentage entrapment of a drug was calculated 
according to Equation 2 
% Drug Entrapment = (W-w/W) × 100        …..(2) 
Particle Size, Particle Size Distribution, and Zeta 
Potential 
The particle size and particle size distribution of the 
formulation was determined by photo correlation 
spectroscopy with a zeta master (Malvern Instruments, 
UK) equipped with the Malvern PCS software. Every 
sample was diluted with distilled water. The surface charge 
(Zeta potential) was determined by measuring the 
electrophoretic mobility of the nanoparticles using a 
Malvern zeta sizer (Malvern Instruments, UK). Samples 
were prepared by diluting with distilled water. 
Polydispersity Index 
Polydispersity index is a parameter to define the particle 
size distribution of nanoparticles obtained from photon 
correlation spectroscopic analysis. It is a dimensionless 
number extrapolated from the autocorrelation function 
and ranges from a value of 0.01 for mono dispersed 
particles and up to values of 0.5-0.7. Samples with very 
broad size distribution have polydispersity index values > 
0.7. 
Percentage yield: 
The prepared microspheres of all batches were accurately 
weighed. The measured weight of prepared microspheres 
was divided by total amount of all the excipients and drug 
used in preparation of the microspheres, which give the 
total percentage yield of microspheres. 
It was calculated by using following equation; 
                       Actual weight of product 
 (%) =       
              Total weight of excipients and drug  
In vitro dissolution studies  
The dissolution profiles of Labetalol Microspheres were 
investigated with a dissolution apparatus (LAB INDIA DS-
8000), according to type II paddle method, with the 
rotation speed of paddle was set on 50 and the bath 
temperature was kept at 37.0 ± 0.5oC. Equivalent 100 
percent of drug preparation was filled into the empty 
capsule. The capsule was put into the vessel containing 
900ml of PH 1.2 HCl buffer for 2 hours, followed by alkaline 
dissolution medium pH 7.4 phosphate buffer for 10 hours. 
To avoid the float of capsule sinkers were used. At specific 
intervals, 5ml of aliquot of dissolution medium was 
sampled, filtered the sample by the U.V-Visible 
spectrophotometer. Absorbance of the sample solution 
compared with the standard solution having a known 
concentration of Labetalol. 
RESULTS AND DISCUSSION 
The method of nanoprecipitation was used so as to avoid 
both chlorinated solvents and surfactants to prevent their 
toxic effect on the body. All the determinations were done 
in triplicate. 
Drug-loading and entrapment efficiency 
Although drug loading expresses the percent weight of 
active ingredient encapsulated to the weight of 
nanoparticles, entrapment efficiency is the ratio of the 
experimentally determined percentage of drug content 
compared with actual, or theoretical mass, of drug used for 
the preparation of the nanoparticles. The loading efficiency 
depends on the polymer-drug combination and the method 
used. Hydrophobic polymers encapsulate larger amounts 
of hydro phobic drugs, whereas hydrophilic polymers 
entrap greater amounts of more hydrophilic drugs. Several 
formulation parameters, such as emulsifier type, weight 
ratio of polymer to drug, and organic to aqueous phase 
ratio, will influence the extent of drug loading. The effect of 
polymer on drug loading efficiency and entrapment 
efficiency are given in Table. 
  
Table 1: Drug loading and Entrapment efficiency 
S.No. Formulation code Drug  : Polymer Loading efficiency ± SD Entrapment efficiency ± SD 
1 F 1 1:2 24.23 ± 0.3 45.6 ± 0.6 
2 F 2 1:2 29.62 ± 0.2 64.3 ± 0.6 
3 F 3 1:2 38.72 ± 05 81.4 ± 0.8 
4 F 4 1:2 32.41 ± 0.2 83.47 ± 1.0 
* = Average of three determinations 
 
Particle Size Distribution and Polydispersity Index 
The particle size and particle size distribution are critical 
factors in the performance of nanoparticles, as batches 
with wide particle size distribution show significant 
variations in drug loading, drug release, bioavailability, and 
efficacy. Particle size and particle size distribution can be 
determined using light scattering techniques and by 
scanning or transmission electron microscopy. 
Formulation of nanoparticles with a narrow size 
distribution will be a challenge if emulsion cannot be 
produced with a narrow droplet size distribution. As 
nanoparticles are internalized into cells by endocytosis, an 
increase in particle size will decrease uptake and 
potentially, affect bioavailability of the drug. The extent of 
endocytosis is dependent on the type of the target cell. 
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Table 2: Drug polymer ratio, mean particle size, particle size distribution, poly dispersity index (PDI) and zeta potential. 
F.  Code Polymer 
Mean Particle Size 
(nm) ± SD 
Size Distribution PDI ± SD 
Zeta Potential 
(mV) ± SD 
F 1 Ethyl 
cellulose 
140.5 ± 1 
09.1% (15-30 nm) 90.9 % 
(200-400 nm) 
1.2 ±0.10 25.7± 1.2 
F 2 
Chitosan 320..6 ± 2 
08.8% (48-90 nm) 91.2% 
(200-525 nm) 
1.6 ±0.12 21.1±1.5 
F 3 
Gelatin 640..3 ± 4 
12.2% (70-160 nm) 80.8% 
(480-1200 nm) 
1.7±0.13 12.2±1.5 
F 4 
HPMC 142.05 ± 2 
11.1% (15-30 nm) 89.9 % 
(200-400 nm) 
1.2 ±0.15 25.5±1.2 
* = Average of three determination 
 
From the above data it is clear that nanoparticles prepared 
by using chitosan and HPMC exhibited reduction in mean 
nanoparticulate diameter and narrower granulometric 
distribution. But the nanoparticles prepared using gelatin 
as a polymer resulted in nanoparticulate population of 
large particles. The higher particle size and polydispersity 
index may be because of absence of emulsifier as the use of 
emulsifier decreases the surface tension between organic 
phase acetone and aqueous phase and leads to the 
formation of smaller solvent droplets, which in turn causes 
decrease in particle size. It also stabilizes newly generated 
surfaces and prevents aggregation of the particles as 
reported by previous researchers. Therefore results which 
were obtained in this study may be improved by using 
increased drug:polymer ratio, using different formulation 
strategy such as desolvation (for gelatin and albumin) or 
counter ion induced aggregation (for chitosan and sodium 
alginate), employing cross linking agent followed by 
neutralizing residual cross linking agent with cysteine and 
high speed stirring. 
Zeta Potential 
The measurement of the zeta potential allows predictions 
about the storage stability of colloidal dispersions. In 
general, particle aggregation is less likely to occur for 
charged particles (i.e. high zeta potential) due to electric 
repulsion. Generally, Zeta potential values above 30 mV 
(positive or negative values) lead to more stable 
nanocapsule suspensions because repulsion between the 
particles prevented their aggregation. A decrease in zeta 
potential, i.e. electrostatic repulsion, was considered as the 
cause for the aggregation process. The charge on the 
surface of the nanospheres will influence their distribution 
in the body and the extent of uptake into the cells. Because 
cell membranes are negatively charged, there is greater 
electrostatic affinity for positively charged nanoparticles. 
Therefore, the surface of cationic or neutral nanoparticles 
may be modified to confer a positive charge to enhance 
efficacy. The zeta potential values which were in the range 
of –24.3 - +25.9 mV, indicates that the colloidal suspension 
may not be stable and may lead to aggregation. Zeta 
potential values can be altered by modifying the major 
components such as surfactants, polymer, and surface 
composition of the nanoparticles, the presence or the 
absence of adsorbed compounds, composition of the 
dispersing phase, mainly the ionic strength, and the pH. 
 
Figure 2: Calibration curve of  Labetalol in pH 7.4 
Phosphate buffer
 
 
Comparative Study 
Table 3:  comparative study of % CDR 
TIME (hrs) %CDR F 1 %CDR F 2 %CDR F 3 %CDR F 4 
0 0 0 0 0 
1 18.05 21.66 25.27 32.49 
2 21.66 25.27 32.49 36.10 
3 30.32 35.37 44.76 51.98 
4 31.76 38.98 49.09 54.15 
5 34.65 43.32 53.42 59.2 
6 36.82 46.2 54.87 63.53 
7 40.43 49.09 57.76 66.42 
8 43.32 52.7 61.37 70.03 
9 47.65 56.31 65.7 72.2 
10 51.26 59.2 69.31 75.81 
11 54.87 62.81 72.92 80.14 
12 60.64 66.42 75.81 83.03 
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Figure 3: Comparative Dissolution Profile graph for 
Formulation F1-F4 
Inference: Microspheres showed highest release within 12 
hours and Formulation F4 showed better sustained release 
than the remaining formulations. 
CONCLUSION 
Among different nanoparticulate formulations prepared by 
nanoprecipitation method formulation F4, with HPMC in 
1:2 drug: polymer ratio, showed satisfactory results; i.e. 
mean particle size of 142 nm (majority of the particles 
were in the range of 150-500 nm), polydispersity index of 
1.2, zeta potential of 25.5 and loading efficiency of 32.41 %, 
and entrapment efficiency of 83.47 % and in vitro drug 
release as pes specifications. 
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